UNSPSC 51283109: Micafungin sodium

This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IS1UP79R56. European Medicines Agency schedules Micafungin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20666. Micafungin sodium generally arises in the molecular formula C56H70N9O23S.NA. The term 'micafungin sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule micafungin sodium under HS 29419000 and SITC 54139.

UNSPSC 51283109 Micafungin sodium is a Commodity code for a specific antifungal pharmaceutical ingredient, yet recent state and local opportunities tagged under it show little activity directly aligned with this narrow scope. The two most-recent opportunities on record—an Illinois Department of Public Health pharmaceutical warehouse piggyback contract and a Seminole County, Florida procurement for naloxone and drug deactivation systems—involve different active pharmaceutical ingredients (doxycycline, ciprofloxacin, and naloxone) rather than micafungin sodium itself. The Illinois contract, awarded to Chartwell Rx LLC for $2,999,999.11 over three years including renewals, supplied antibiotics through the MMCAP Infuse consortium purchasing vehicle; the Seminole County solicitation, posted in mid-2026, sought 1,900 units of naloxone and 800 drug deactivation systems annually through a two-year term with one-year renewal. Both opportunities reflect state and local health agencies sourcing pharmaceuticals and medical supplies through competitive bidding, but neither demonstrates active procurement of micafungin sodium specifically.

The geographic spread evident in these records spans Illinois (state health department) and Florida (county health authority), with no additional jurisdictions showing recent micafungin-tagged opportunities. The code shows minimal recent activity—only two opportunities across the past several months, both mismatched to the commodity's stated scope—suggesting either light current demand for micafungin sodium in state and local procurement or systematic misclassification of pharmaceutical line items at the Commodity tier within these jurisdictions' procurement systems. Business development teams should verify whether micafungin procurement occurs under higher-tier pharmaceutical codes (Family or Class level) or through cooperative purchasing consortia that may not tag individual drug SKUs at the Commodity level.